

# PROVINCIAL FUNDING SUMMARY

Ribociclib (Kisqali) for Advanced or Metastatic Breast Cancer (pCODR 10194)

pERC Recommendation: Reimburse with clinical criteria and/or conditions  
 For further details, please see [pERC Final Recommendation](#)

Notification to Implement Issued by pCODR: June 19, 2020

This information is current as of October 1, 2020.

Note: Funding criteria as listed on the decision date. Please refer to the provincial drug programs for the most recent funding criteria and program eligibility.

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
BC	Under provincial consideration		
AB	Under provincial consideration		
SK	Funded	Aug 1, 2020	<ul style="list-style-type: none"> <li>•In combination with Anastrozole or Letrozole for the treatment of post-menopausal women or men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer who have not received any prior endocrine treatment for advanced or metastatic disease</li> <li>•Treatment may continue until unacceptable toxicity or disease progression; patients should have good performance status and not be resistant to prior neoadjuvant or adjuvant non-steroidal aromatase inhibitor (NSAI) therapy (e.g., patients should be disease-free for at least one year from the completion of prior adjuvant NSAI therapy), nor have active or uncontrolled metastases to the central nervous system Notes:</li> <li>•Eligible patients include men and women independent of their menopausal status; pre and peri-menopausal women must be rendered postmenopausal, either chemically or surgically, and should be treated with a luteinizing hormone-releasing hormone (LHRH) agonist or bilateral salpingo-oophorectomy</li> </ul>
MB	Under provincial consideration		
ON	Under provincial consideration		
NS	Under provincial consideration		

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
NB	Funded	Sep 17, 2020	In combination with an aromatase inhibitor for the treatment of patients with hormone receptor positive, HER2 negative advanced or metastatic breast cancer who: <ul style="list-style-type: none"> <li>• have not received prior endocrine therapy for advanced or metastatic disease, and</li> <li>• are not resistant to prior (neo)adjuvant non-steroidal aromatase inhibitor (NSAI) therapy, and</li> <li>• do not have active or uncontrolled metastases to the central nervous system.</li> </ul> Renewal criteria: <ul style="list-style-type: none"> <li>• Written confirmation that the patient has responded to treatment and there is no evidence of disease progression.</li> </ul> Clinical Notes: <ol style="list-style-type: none"> <li>1. For patients who received (neo)adjuvant NSAI therapy, a minimum disease-free interval of twelve months after stopping therapy is required.</li> <li>2. Pre- and peri-menopausal women must be treated with a luteinizing hormone-releasing hormone agonist.</li> <li>3. Patients must have a good performance status.</li> <li>4. Treatment should be discontinued upon disease progression or unacceptable toxicity.</li> </ol> Claim Notes: <ul style="list-style-type: none"> <li>• Requests will be considered for patients who have received up to one prior chemotherapy for advanced or metastatic disease.</li> <li>• Initial approval period: 1 year.</li> <li>• Renewal approval period: 1 year.</li> </ul>
NL	Under provincial consideration		
PEI	Under provincial consideration		

*Under provincial consideration* means that the province is reviewing pCODR's recommendation. This may include the province working with the drug manufacturer to reach an agreement for a drug product that both parties can accept, in particular in cases where the pCODR Expert Review Committee has recommended that the drug be funded only on the condition of cost-effectiveness being improved to an acceptable level. This may occur before or after the pan-Canadian Pharmaceutical Alliance negotiations. Please contact the specific provincial drug program and/or cancer agency in your province for information about the status of a given drug product.